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Abstract: Treatment of trigeminal neuralgia (TN) is achieved by using adjuvant analgesics like 
antiepileptics, with carbamazepine (CBZ) being the first-line approach for TN patients, although 
side effects may be present. Other approaches using gabapentin, namely when associated with 
peripheral analgesic block of TN trigger points with the local anesthetic ropivacaine (ROP), 
resulted in decreased pain and daily drug intake (reduced side effects). This study evaluates if 
the association between CBZ and the peripheral block with ROP reinforces the clinical value of 
CBZ. In this parallel, double-blinded study, idiopathic TN patients were randomized to receive 
during 4 weeks either CBZ (CBZ; n = 21) or CBZ associated with the peripheral analgesic 
block using ROP (CBZ + ROP; n = 24). The primary outcome measures were the following: i) 
pain intensity, evaluated by the numerical rating scale; ii) number of pain crises; and iii) number 
needed to treat. Evaluation points were at the beginning (day 1) and end (day 29) of treatment and 
after a follow-up of 5 months (month 6). Both protocols resulted in a decrease of pain intensity 
and number of pain crises, but only the association CBZ + ROP showed i) a significant stronger 
reduction in pain intensity at month 6 and ii) a significant decrease in the daily dose of CBZ 
given to patients (both at day 29 and month 6). In contrast, the daily dose in CBZ-only patients 
remained constant or even increased. The number needed to treat for the association CBZ + ROP 
over the CBZ protocol reduced from 5 at the end of the 4-week treatment to 3 after the 5-month 
follow-up. Data reinforce the use of CBZ as a primary tool to control pain in TN patients, as the 
association CBZ + ROP i) improves the clinical qualities of CBZ, ii) strongly reduces the daily 
dose of CBZ, and iii) reduces the potential side effects attributed to high doses of CBZ.
Keywords: trigeminal neuralgia, carbamazepine, ropivacaine, therapeutical association, pain 
intensity, daily dose
Introduction
Neuropathic pain is a form of pain caused by a lesion or disease of the peripheral or 
central nervous system.1,2 It is a challenging condition to treat because of the following 
reasons: i) the heterogeneity of etiologies, symptoms, and underlying mechanisms; 
ii) poor response to conventional analgesics; and iii) the tendency for treatment being 
performed in a uniform fashion across the patient population.3 Trigeminal neuralgia 
(TN) (annual incidence of 4–5/100,000)4 is a type of neuropathy  characterized by 
periods of intense paroxystic pain, usually of short duration and triggered by  innocuous 
stimuli, although resulting in excruciating pain.5,6 A large number of cases of TN are 
idiopathic (primary or asymptomatic TN), usually with no detectable structural nerve 
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lesion (includes the potential vascular compression of the fifth 
nerve in 15% of these patients) and a normal neurological 
evaluation.7,8 Like in other neuropathies, classic analgesics 
most frequently have no beneficial effects in controlling 
TN pain, even in secondary (symptomatic) TN, when it is 
associated with identifiable structural lesions, like a tumor or 
multiple sclerosis. Treatment is achieved by using adjuvant 
analgesics like antiepileptics (AE) and antidepressives.6,8 
Contrary to other neuropathies, which use gabapentin as 
first-line treatment,1,9,10 the AE carbamazepine (CBZ) has for 
a long time been and still is considered the first-line pharma-
cological approach for TN patients.5–8,11,12 Several drawbacks 
are associated with CBZ intake. It produces a toxic epoxide 
metabolite and regular blood tests are thus recommended; it is 
also associated with 10% incidence of rashes, has a negative 
effect on bone density, may induce abnormal liver function, 
may result in interstitial pneumonitis, and presents significant 
interactions with other drug classes.3,6,8,12,13 Oxcarbazepine 
may be used in TN patients unresponsive to CBZ6,14 and, as 
second-line drugs, baclofen, lamotrigine,8 and pregabalin15/
gabapentin12,16–21 are at front line.
In cases of CBZ intolerance, hypersensitivity, drug 
interactions or a narrower therapeutic index, and a higher degree 
of adverse side effects, gabapentin can be used as a second-line 
treatment.12,16–21 Recently, a combination of different drugs have 
been used to treat TN.7 When gabapentin is associated with 
the peripheral analgesic block of TN trigger points with the 
local anesthetic ropivacaine (ROP), the result is a significant 
decrease of pain intensity scores, number of paroxystic pain 
crises, and daily drug intake.21 As a consequence of smaller 
gabapentin doses during the combination gabapentin + ROP, 
a reduction of adverse side effects is obtained when compared 
with gabapentin in monotherapy, the latter presenting 
already a much lighter pattern of side effects than CBZ in 
monotherapy.12 Finally, one main objective of the clinical 
approach to TN, the functional capacity for the patients, was 
shown to be significantly improved when associating the oral 
intake of gabapentin with the peripheral block of  TN trigger 
points with ROP.21 Following these data,21 the objective of the 
present study is to evaluate if a similar association between 
CBZ and the peripheral analgesia of  TN trigger points with 
ROP reinforces the clinical value of CBZ as major therapy for 
TN, by reducing pain intensity scores, daily drug doses, and 
adverse side effects.
Methods
The methodology followed in the present study is reported 
as possible to the recent recommendations of the CONSORT 
group for improving the quality of reports of parallel-group 
randomized trials.22
Patients – inclusion and exclusion criteria
Out of 48 patients with idiopathic TN and uncontrolled 
pain arriving at the Fafe Pain Unit of the Hospital Center 
of Alto Ave (Fafe, Portugal), 45 were randomly treated 
during 4 weeks with the traditional approach of CBZ in 
monotherapy (CBZ protocol; n = 21) or with the new protocol 
CBZ associated with the peripheral analgesic block of TN 
trigger points with ROP (CBZ + ROP protocol; n = 24) 
(Figure 1). Two patients were excluded before allocation 
due to the presence of multiple sclerosis, and one patient 
allocated to CBZ protocol was excluded at day 1 due to an 
allergic reaction to CBZ (Figure 1). Patients were eligible 
for the study if they presented a pain intensity measured by 
the numerical rating scale (NRS) with a score $6 (from a 
0–10 scale) and met the consensus criteria for the diagnosis 
of primary  (idiopathic) TN.6,7,23 The inclusion criteria were 
the following: i)  occurrence of episodes of facial  paroxysmal 
pain in territory innervated by one or more branches of the 
trigeminal nerve (NRS score $6); ii) trigger areas (if touched 
lightly, will provoke an episode of pain);19,21 iii) normal 
neurological examination; iv) normal neuroimaging analysis 
following a CT scan or MRI; and v) symptoms not attributed 
to another disorder.
On the other hand, the following exclusion criteria 
were also considered: i) patients refuse to participate; 
ii) psychological instability (clinical depressive condi-
tion); iii) atypical pain location (eg, no specific trigger 
points); iv) secondary  (symptomatic) TN6 (multiple scle-
rosis, temporomandibular joint disorders, and neoplasms); 
v) altered neurological profile (hypoesthesia, dysesthe-
sia, anesthesia, and paresis); vi) association with other 
 cranial nerve neuralgias (eg, glossopharyngeal  neuralgia); 
vii) imagiological alterations (neoplasms, abnormal 
 vasculature, or intracranial pathology) observed in CT 
scan or MRI; and viii) proposed surgical intervention 
(compression of the Gasser ganglion confirmed by ima-
giology; preference of the patient in cases of uncontrolled 
pain and adverse side effects).
The therapeutic protocols used were accepted by 
the Hospital Ethical Committee and the patients were 
informed that i) they were going to be submitted to one 
of two different treatment protocols to solve their pain 
problem and ii) they could drop or change treatment if 
no pain control was achieved. All patients signed an 
informed consent.
Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
203
carbamazepine–ropivacaine in treating trigeminal neuralgia
Random allocation and treatment 
protocols
The 45 TN patients entering the study were the first arriving 
to the Chronic Pain Unit and fulfilling the inclusion criteria. 
There were 2 days in the week (Monday and Thursday) for 
pain consult at the unit, with those patients arriving in the first 
day being assigned to one treatment group and those arriving 
in the second day of the week being attributed to the second 
therapeutic protocol. Thus, there was no sequential attribution 
of protocols CBZ or CBZ + ROP, with patient random allo-
cation being solely dependent on the day of presentation at 
the Pain Unit. Patients were recruited between January 2006 
and October 2008. None of the patients included in the 
present study had participated in the previous TN study of 
our group.21 Patients were allocated to one of the following 
treatment protocols (Figure 1): i) protocol CBZ + ROP and 
ii) protocol CBZ.
Protocol cBZ + ROP
Treatment using CBZ given orally plus ROP administered 
superficially at TN facial trigger points. These were pointed by 
the patients as the exact area of the face that usually induces 
pain when touched. The peripheral analgesic block with ROP 
was performed at the Pain Unit under sterile conditions, using 
Assessed for eligibility
(n = 48)
Randomized study
(N = 46)
Enrollment
Excluded before allocation (n = 2):
  Multiple sclerosis (n = 2)
Protocol CBZProtocol CBZ + ROP
Allocation
Day 1
Analysis (NRS scale; Nr crisis)
Day 1
Analysis (NRS scale; Nr crisis, NNT)
Month 6
Analysis (NRS scale; NNT)
Day 28
Analyzed
(n = 24)
Excluded from analysis
(n = 0)
Analyzed
(n = 24)
Excluded from analysis
(n = 0)
Follow-up: 5 months after protocol
(n = 24)
Lost to follow-up
(n = 0)
Discontinued intervention
(n = 0)
Follow-up: 5 months after protocol
(n = 21)
Lost to follow-up
(n = 0)
Discontinued intervention
(n = 0)
Analyzed
(n = 21)
Excluded from analysis
(n = 0)
Analyzed
(n = 21)
Excluded from analysis
(n = 0)
Allocated to intervention
(n = 22)
Did not receive allocated intervention
(n = 1; alergic reaction to CBZ)
Received allocated intervention
(n = 21)
Allocated to intervention
(n = 24)
Did not receive allocated intervention
(n = 0)
Received allocated intervention
(n = 24)
Figure 1 Flowchart of the steps followed by Tn patients along the experimental design of the study. note that out of 48 Tn patients who were assessed to participate in 
this study, 2 were excluded before allocation owing to exclusion criteria, and 1 cBZ patient was excluded during day 1.
Abbreviations: cBZ, carbamazepine; ROP, ropivacaine; nRs, numerical rating scale; nr, number; nnT, number needed to treat; Tn, trigeminal neuralgia.
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a 27-gauge needle for administering subcutaneously 2 mL of 
a 2 mg/mL ROP solution21,24 in each trigger point. Each local 
block was performed once a week21,25 during the 1 month 
treatment (days 1, 8, 15, 22, and 29). When patients arrived 
to the Pain Unit (day 1) who had been referred from other 
health institutions, they presented uncontrolled pain under a 
CBZ dose of 400–1000 mg/day. From the first day, the CBZ 
dose taken by each patient could increase gradually until 
1200 mg/day if the pain intensity reached or kept an NRS score 
$6, or gradually reduced if pain control was regained. Every 
7 days, during their visit to the Pain Unit, the NRS score of 
the patient was recorded and CBZ dose adjusted if necessary, 
each alteration being performed in steps of 200 mg/day.6
Protocol cBZ
This treatment is done using only CBZ in monotherapy. 
Patients entering this protocol received additionally a control 
injection of saline (the vehicle of ROP administered in the 
other protocol, CBZ + ROP) at facial trigger points, every 
7 days of treatment (days 1, 8, 15, 22, and 29). Although the 
usual CBZ effective dosage ranges between 400–600 and 
1000–1200 mg/day,6,26 when patients with uncontrolled pain 
referred from other health institutions arrived at the Fafe Pain 
Unit (day 1), their CBZ dose (whatever it was) was increased 
by 200 mg/day;6 thus, no titulation of the drug was performed 
in order to avoid clinical instability of patients and ethical 
issues. Every 7 days, during their visit to the Pain Unit, 
the NRS score of the patients was recorded and CBZ dose 
adjusted if necessary.
experimental sequence
During the 29 day treatment,21 all patients were evaluated by 
the hospital staff at day 1 and then periodically at days 8, 15, 
22, and 29 (1-month treatment). During the periods between 
days 2 and 7, 9 and 14, 16 and 21, and 23 and 28, patients 
were at home and were requested to record their NRS pain 
intensity score in an individual pain diary provided by the 
staff plus the CBZ dose, the hour when medication was taken, 
and side effects observed.
Paracetamol (acetaminophen) was used in this study for 
breakthrough pain in those cases where patients needed pain 
control between CBZ doses, or if the medication prescribed 
in the protocol was not having an analgesic effect. They were 
instructed to take it as needed every 8 hours with a maximum 
of 3000 mg/day, in order to avoid a potentiation of the toxic 
effect of CBZ at the hepatic level.
After the 1-month period of treatment, patients from both 
protocols were requested to continue their treatment at home, 
using the same CBZ dose used at day 29. If patients during 
the 5-month follow-up experienced a new pain episode, they 
were instructed to return to the Pain Unit for evaluation and 
readjustment of the treatment or, alternatively, they were 
provided with the most adequate conventional treatment.
Double-blinded study
This study was blinded to both the authors and patients. 
In what concerns the authors, firstly, the application of 
each protocol treatment to the patients was performed by a 
researcher who was blinded i) to the content of the peripheral 
injections (saline or ROP), which were prepared by another 
member of the Pain Unit; ii) to the NRS scores evaluation 
of pain intensity; and iii) to the number of daily pain crisis 
of each patient. Secondly, NRS scores and number of pain 
crisis were evaluated by a second researcher, who was 
blinded to the protocol assigned to each patient. Thirdly, 
the statistical evaluation of the data was performed by a 
third researcher, who was not a health service professional 
and was not aware of the clinical implications of protocols 
CBZ and CBZ + ROP. All these precautions resulted in a 
study blinded to the authors. In what concerns the patients, 
as already stated for the informed consent of the patients, 
they were not aware of which protocol was being applied to 
them, as all of them were taking i) oral CBZ and ii) an injec-
tion (saline or ROP). In a previous study,21 a third group of 
patients has been submitted to a protocol of ROP only (which 
implied absence of a blinded study to the patients) besides 
a gabapentin monotherapy group and a gabapentin + ROP 
protocol. However, the clinical insecurity of a ROPonly 
protocol21 resulted, in the present study, in the evaluation 
of only two protocols, which allowed a study blinded also 
to the patients: CBZ monotherapy (with injection of saline) 
and CBZ + ROP (with injection of ROP).
Primary outcome measures
The predef ined primary outcome measures were the 
following:
1. Evaluation of pain intensity using the NRS scale: Evalu-
ation points for statistical analysis were at the arrival to 
the Pain Unit (day 1), at the end of the treatment (day 29), 
and after a follow-up of 5 months (month 6). Patients 
classified their pain between 0 (no pain) and 10 (the worst 
pain imaginable). The number corresponding to the pain 
felt was chosen by each patient in the interview with the 
nurse. The evaluation of pain intensity at days 1 and 29 
was performed in the Pain Unit, whereas at month 6 it was 
performed during a phone interview (see the  following 
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paragraph). A pain reduction of 2 points in the NRS scale 
when compared with the baseline pain score (day 1) was 
considered clinically significant.27–31
2. Daily number of paroxysmal pain episodes: Only data 
obtained at day 1 and 5 months after the end of the treat-
ment (follow-up; month 6) were used for statistical analy-
sis. The follow-up evaluation was performed at the end of 
the day of performing month 6, during a phone interview 
to each patient, who was asked i) how many pain attacks he 
or she had suffered during that day (and the pain intensity 
in the NRS scale) or, in case of no pain, ii) how many pain 
crises he or she had suffered in the worst day of the last 
week before interview (and the highest pain intensity in 
the NRS scale). If no pain was recorded following these 
two questions, the staff recorded 0 (zero) crisis for the 
patient at month 6 (and 0 in the NRS scale).
3. Number needed to treat (NNT): The NNT is an estimate 
of the number of patients that would need to be given 
a treatment for one of them to achieve a desired out-
come.31,32 Following the rationale of a previous study,21 
we compared the therapeutic result between a new pro-
posed therapy (GBP + ROP protocol) and a conventional 
treatment (CBZ protocol), as suggested by Altman.33 This 
allows a comparison of efficacy between the two clini-
cal treatments.33 Accordingly, in the present study, NNT 
is defined as 1/[the proportion of patients successfully 
treated with CBZ + ROP (with at least 50% pain relief) 
– the proportion of patients successfully treated with the 
standard CBZ monotherapy], as expressed in the equation 
below. The NNT of protocol CBZ + ROP over protocol 
CBZ was determined for day 29 (comparing with the 
baseline values at day 1) and month 6 (comparing with 
baseline values at day 29). The 95% confidence interval 
(CI) for each NNT result was obtained using the free 
calculator at the site of the University of Manchester: 
www.phsim.man.ac.uk/nnt/
daily dose of CBZ would reflect the necessity for pain control 
and the potential presence of adverse side effects.
statistics
Data are presented as average ± standard deviation (SD) 
along the several variables under study. The chi-square test 
was used to compare the distribution of the cases by treat-
ment versus age, sex, pain location, and facial side. The 
normal distribution of the results was verified using the 
Kolmogorov–Smirnov test, whereas the equality of vari-
ances was evaluated by the Levene’s test. A comparison of 
the means of NRS values, number of pain crises, and CBZ 
dosages of protocols CBZ + ROP and CBZ was performed 
at each statistical evaluation point (day 1, day 29, month 6 
for NRS and CBZ dosage data; day 1 and month 6 for the 
number of pain crisis) using the Student’s t-test for equality 
of means.
Results
Patient baseline characteristics
Out of 48 patients assessed for eligibility, 46 patients were 
randomly allocated to one of the two therapeutical proto-
cols (Figure 1). Two patients were excluded because they 
had multiple sclerosis. Twenty-four were assigned to pro-
tocol CBZ + ROP and 22 to protocol CBZ. However, one 
CBZ patient had to be excluded at day 1 due to an allergic 
reaction to CBZ. Thus, only 21 patients followed the CBZ 
protocol (Figure 1; Table 1). Figure 1 summarizes the flow 
of patients throughout the experimental protocol of this 
study. The baseline data for the demographic characteristics 
of patients selected for both protocols, their comorbidities, 
and their concomitant drug therapies are given in Table 1. 
No statistical significant differences were present between 
CBZ + ROP and CBZ groups of patients in what concerns 
age, sex, pain location (number of trigeminal branches 
affected), and facial side affected (P . 0.05 in all compari-
sons), showing that similar sets of patients were randomly 
allocated to both treatments. No differences were also 
observed in the percentage of CBZ + ROP and CBZ patients 
without any known comorbidity (42% and 33%, respectively) 
and in the percentage of those presenting hypertension, the 
most frequent comorbidity (42% and 38%) observed in 
these TN patients (Table 1). Occasional cases occurred of 
diabetes mellitus type 2, stroke, epilepsy, depression, and 
cardiac or thyroid pathology. In what concerns concomitant 
drug therapies, the most common drugs used in addition to 
CBZ + ROP/CBZ were antihypertensors (18 of the 45 TN 
patients): three CBZ patients were taking anticoagulants, 
NNT 
=
1
50% nRs reduction 
cBZ + ROP patients
- 50% nRs reduction cBZ-only 
patients
Total number of 
cBZ + ROP patients
Total number of cBZ-only 
patients
secondary outcome measure
A secondary outcome measure of this study was the evolu-
tion of daily dosage of CBZ following the 1-month treatment 
under protocols CBZ + ROP and CBZ (day 1 and day 29) 
and after a follow-up of 5 months (month 6). Changes in the 
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two  antiarrhythmics or antihypothyroidism drugs, and one 
another anticonvulsivant, whereas 1 CBZ + ROP patient was 
taking an antidepressant (Table 1).
effect of cBZ + ROP and cBZ protocols 
in pain control
No differences were found between patients from protocol 
CBZ + ROP (NRS
1
 = 9.1 ± 1.1) and protocol CBZ 
(NRS
1
 = 9.1 ± 1.4) (P = 0.887) (Figure 2; Table 2) in pain 
intensity at the beginning of the treatment (day 1). This result 
reinforces the homogeneity of the participants and the similarity 
between patients allocated to the two protocols. At the end of 
the treatment (day 29), both protocols significantly reduced 
pain intensity (CBZ + ROP
(1–29)
, NRS  difference = 6.3, 
P , 0.0001; CBZ
(1–29)
, NRS difference = 5.2, P , 0.001), but 
CBZ + ROP therapy resulted in a significantly stronger pain 
reduction than patients following CBZ protocol (CBZ + ROP, 
NRS
29
 = 2.8 ± 0.8; CBZ, NRS
29
 = 3.8 ± 1.0; P , 0.001) 
(Figure 2; Table 2). After 5 months, both protocols significantly 
reduced pain intensity when compared with day 1 
(CBZ + ROP
(1–6m)
, NRS difference = 7.0; P , 0.0001; CBZ
(1–6m)
, 
NRS difference = 5.1; P , 0.0001). However, significant dif-
ferences were observed again between the two protocols, with 
CBZ + ROP inducing a significantly stronger reduction in pain 
intensity than CBZ alone (CBZ + ROP, NRS
6m
 = 2.0 ± 0.7; 
CBZ, NRS
6m
 = 3.9 ± 1.4; P , 0.0001) (Figure 2; Table 2).
The baseline number of daily crises of paroxysmal 
sudden and intense pain was similar between patients of 
both protocols (day 1: CBZ + ROP, n
crises
 = 9.6 ± 2.3; CBZ, 
n
crises
 = 10.6 ± 2.2; P = 0.131) (Figure 3; Table 2). It was not 
possible to obtain data from the end of the 4-week treatment 
(day 29). After a follow-up of 5 months, both protocols 
reduced the number of daily crises (CBZ + ROP
(1–6m)
, dif-
ference = 7.0; P , 0.0001; CBZ
(1–6m)
, difference = 6.5; 
P , 0.0001), with patients treated with CBZ + ROP protocol 
showing a significantly stronger reduction than those under 
CBZ monotherapy (month 6: CBZ + ROP, n
crises
 = 2.5 ± 0.5; 
CBZ, n
crises
 = 4.1 ± 1.7; P , 0.0001) (Figure 3; Table 2).
nnT
When comparing the clinical benefit obtained by CBZ + 
ROP, the NNT for the treatment associating CBZ + ROP 
over the CBZ protocol was 5.25 (95% CI: 2.48–27.95) at 
the end of the 4-week period of treatment (day 29), but 
reduced to 3.11 (95% CI: 1.84–15.33) after a follow-up of 
5 months (month 6). Thus, 5 and 3 are the estimated number 
of patients (at day 29 and at month 6, respectively) who need 
to be treated with the new treatment (CBZ + ROP protocol) 
rather than the standard treatment (CBZ protocol) for one 
additional patient to benefit.21,33
cBZ daily dose
When arriving at the Pain Unit from other health center 
 institutions (day 1), patients beginning the CBZ + ROP proto-
col were taking 836 ± 253 mg/day of CBZ, and patients start-
ing the CBZ protocol were taking 626 ± 163 mg/day of CBZ 
(Figure 4). At the end of the treatment, the CBZ daily dose has 
been significantly reduced in patients with CBZ + ROP protocol 
while CBZ intake even increased in patients submitted to CBZ 
 monotherapy (day 29: CBZ + ROP
dose
 = 525 ± 165 mg/day; 
CBZ
dose
 = 757 ± 200 mg/day; P , 0.0001) (Figure 4; 
Table 1 Baseline characteristics of Tn patients
Protocol 
(CBZ + ROP) 
(n = 24)
Protocol 
(CBZ) 
(n = 21)1
P value
Age (years, average, 
and sD)
64 (12.5) 68 (10.7) 0.249
sex (women/total) 15/24 18/21 0.709
Pain location (nerve 
branches)
0.745
V1 or V2 or V3 11 12
V1 + V2 or V2 + V3 9 6
V1 + V2 + V3 4 3
Facial side (right/total) 15/24 10/21 0.316
Pain duration at day 1
1–5 years 8 9
6–10 years 12 4
11 and more 4 8
no comorbidities 10 7 0.565
comorbidities
hypertension 10 8 0.807
Diabetes mellitus type 2 2 1
Osteoarticular 
pathology
1 1
cardiac pathology2 0 4
stroke 0 1
Depression 1 0
epilepsy 0 1
Thyroid pathology 0 2
concomitant drug therapy
Antihypertensors (angiotensin- 
converting enzyme inhibitors)
10 8
Anticoagulants (warfarin)3 0 3
Antiarrhythmics 
(amiodarone)
0 2
Antidepressants (fluoxetine) 1 0
Anticonvulsants (sodium 
valproate)
0 1
Antihypothyroidism 
(levothyroxine)
0 2
Notes: 1note that the patient allocated to cBZ protocol that was excluded at 
day 1 due to allergic reaction to cBZ was not included in this analysis; 2Arrhythmias 
or valve disease; 3serum levels of warfarin were controlled.
Abbreviations: cBZ, carbamazepine; ROP, ropivacaine; sD, standard deviation.
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Table 2). Finally, after the follow-up period, CBZ intake 
further reduced in CBZ + ROP protocol and resulted in a 
significantly lower final daily dose of CBZ than in patients 
following CBZ protocol (in this case, CBZ intake increased 
again) (month 6: CBZ + ROP
dose
 = 367 ± 183 mg/day; 
CBZ
dose
 = 826 ± 291 mg/day; P , 0.0001) (Figure 4; 
Table 2).
Discussion
CBZ has been a for long time and is still considered the 
first-line pharmacological option for controlling pain in 
TN. However, CBZ often results in adverse side effects and 
intolerance, with these cases being solved by second-line AE 
or antidepressant drugs or, in case of prolonged intolerance, 
a surgical option. In order to improve the clinical outcome 
of CBZ therapy and reduce its unwanted effects, the present 
study evaluated the association of CBZ with the peripheral 
analgesic block of TN trigger points with the local anesthetic 
ROP. A similar approach has resulted in improved efficacy 
when using gabapentin in the treatment of TN.21 The protocol 
associating CBZ + ROP resulted in a significant reduction 
in i) pain intensity, ii) the number of daily pain crises, and 
iii) the daily dose of CBZ intake, when compared with the 
traditional CBZ protocol in monotherapy.
Methodological considerations
The rationale of the present study was to further increase the 
efficacy of first-line drug CBZ in controlling TN pain and, 
Table 2 Outcome results between groups and their statistical 
significance
Protocol 
(CBZ + ROP) 
(n = 24)
Protocol 
(CBZ) 
(n = 21)1
P value
nRs, day 1 9.1 (1.1) 9.1 (1.4) 0.887
nRs, day 29 2.8 (0.8) 3.8 (1.0) ,0.001
Dif nRs, day 1 to day 29 6.3 5.2 ,0.001
nRs, month 6 2.0 (0.7) 3.9 (1.4) ,0.0001
Dif nRs, day 1 to month 6 7.0 5.1 ,0.0001
ncRises, day 1 9.6 (2.3) 10.6 (2.2) 0.131
ncRises, month 6 2.5 (0.5) 4.1 (1.7) ,0.0001
Dif ncRises, day 1 to 
month 6
7.0 6.5 ,0.0001
cBZ dose, day 29 525 (165) 757 (200) ,0.0001
cBZ dose, month 6 367 (183) 826 (291) ,0.0001
Notes: Data are presented as average (sD). 1note that the patient allocated to cBZ 
protocol who was excluded at day 1 due to allergic reaction to cBZ was not included 
in this analysis.
Abbreviations: Dif, difference; nRs, numerical rating scale; ncRises, number of 
crises; sD, standard deviation.
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Figure 2 effect of the 2 protocols (cBZ + ROP and cBZ) on the pain intensity of patients at the end of the 4-week treatment (day 29) and after a 5-month follow-up (month 6). 
no baseline differences were observed in the pain intensity between patients allocated to the two protocols (day 1). note that both after the 4-week treatment and the 
5-month follow-up, cBZ + ROP patients showed a stronger pain reduction than CBZ-only patients. For statistical comparisons and significances, see the Results section.
Abbreviations: cBZ, carbamazepine; nRs, numerical rating scale; ROP, ropivacaine.
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not less important, to reduce potentially the impact of the 
adverse side effects associated with the therapeutic doses 
usually used.12,34,35 In order to eliminate the possibility that 
any beneficial effect could depend on the physical action of 
local administration of the analgesic ROP solution by clear-
ing adhesions or inflammatory molecules from the vicinity 
of the nerve,25 the protocol CBZ-only was accompanied with 
injection of saline to TN trigger points. Thus, the improve-
ments observed in the different outcomes analyzed resulted 
exclusively from the pharmacological action of CBZ + ROP 
and CBZ and not by the manipulation and liquid introduc-
tion at trigger points. An additional advantage of saline 
administration to CBZ-only patients was the possibility of 
performing a treatment blinded to both patients and research-
ers (double-blinded study for the treatment).
The frequency of ROP injections applied subcutaneously 
to TN patients respected the guidelines for the practice of 
interventional techniques.25 A patient should receive an injec-
tion at intervals not smaller than 1 week, which was the period 
chosen to mediate between each ROP (or saline) administra-
tion. The follow-up evaluation of patients treated with both 
protocols (month 6) was performed by phone interview, as 
they were trained since the beginning of this study to classify 
their pain according to a 0–10 scale.
clinical impact of the cBZ + ROP 
association
Because a 2-point decrease in the mean NRS scale 
(0–10 scale) is considered the minimum clinical relevant 
difference in pain intensity when comparing the effect of two 
treatments,27–31 both the CBZ + ROP and CBZ protocols were 
clinically effective in reducing pain after a 4-week therapy. 
In fact, they decreased pain intensity in 6.3 and 5.3 points 
(respectively) after the 4-week therapy. At the end of the 
treatment, the pain reduction obtained by CBZ + ROP was 
significantly stronger than that of CBZ. However, as NRS 
mean was only 1 point smaller after CBZ + ROP than CBZ 
(2.8 versus 3.8), it is questionable whether the statistical 
significant improvement of CBZ + ROP protocol reaches 
a really clinical importance.31 After a 5-month follow-up, 
however, the significant reduction in pain intensity obtained 
by CBZ + ROP patients reached the border of a 2-point 
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Figure 3 number of daily episodes of pain before (day 1) and after a 5-month follow-up (month 6) in patients submitted to cBZ + ROP and cBZ treatments. no baseline 
differences were observed in the number of pain crisis between patients allocated to the two protocols (day 1). After 6 months, cBZ + ROP patients showed a stronger 
reduction in the number of pain crises than those under CBZ protocol. For statistical comparisons and significances, see the Results section.
Abbreviations: cBZ, carbamazepine; ROP, ropivacaine.
Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
209
carbamazepine–ropivacaine in treating trigeminal neuralgia
difference of clinical significance when compared with the 
reduction obtained by CBZ patients (NRS of 2.0 versus 3.9). 
Two aspects must be considered when approaching the dis-
cussion of these data. Firstly, from the end of the treatment 
to 5 months later, the pain intensity in CBZ + ROP patients 
showed a further decrease (2.8 → 2.0), whereas no changes 
were observed in CBZ-treated patients (3.8 → 3.9); secondly, 
the same authors claiming that a 2-point scale decrease is 
the minimum clinical benefit following a pain treatment 
for a ‘much better improvement’ also considered that a 
1-point reduction in the NRS pain scale was felt as ‘slightly 
better,’29 which can also be considered an improvement.31 
In fact, a 1-point reduction in pain intensity represented the 
minimal clinically important difference, as defended by the 
same authors. These data indicate that both at the end of the 
4-week treatment (day 29) and after a follow-up 5 months 
later (month 6), the CBZ + ROP protocol reinforced the pain 
reduction resulting from the traditional CBZ-only protocol. 
This suggests that, as was previously demonstrated for the 
gabapentin and ROP association,21 a potentiation or syn-
ergism between the AE and local analgesic effect occurs 
when CBZ and ROP are associated in the same protocol. 
Previous studies also  indicated that combinations of CBZ + 
gabapentin or  gabapentin +  lamotrigine18 can result in TN 
pain control.
When comparing CBZ + ROP protocol with the standard 
CBZ protocol, another indication of improvement in the clini-
cal outcome is the NNT. The number of patients who must 
be treated by the CBZ + ROP protocol to generate one more 
success than would have resulted had all patients been given 
the comparison treatment (CBZ-only) was 5 after the 4-week 
treatment (day 29) and reduced to 3 after a 5-month follow-
up (month 6). Again, this shows that data 5 months after the 
treatment are more robust in indicating an advantage of the 
combination of CBZ + ROP upon CBZ than immediately 
after the end of the treatment.
Another important therapeutical improvement in the 
combination of CBZ + ROP is the demonstration of a 
large decrease in the daily dose of CBZ intake, both at the 
end of the treatment (day 29) and, even further, after the 
5-month follow-up. On the contrary, CBZ monotherapy 
observed a progressive increment in the daily CBZ dosage. 
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Figure 4 Longitudinal evolution of the daily dose of cBZ taken during treatment (4-week period) protocols cBZ + ROP and cBZ. Therapy with cBZ + ROP clearly reduced 
successively the intake of cBZ from day 1 to day 29 and from the end of the treatment to month 6, whereas cBZ monotherapy resulted in a progressive increase of the 
daily dose of this antiepileptic. For statistical comparisons and significances, see the Results section.
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The typical maintenance CBZ doses applied to TN patients 
seen in the  literature range between 300–800 mg/day,12 
600–800 mg/day,35 200–1200 mg/day,7 400–1200 mg/day,11 
or 600–1200 mg/day.6 In the present study, the CBZ + ROP 
proportioned pain control with a medium daily dose of 
367 mg/day, which points clearly to the lower range of the 
clinical intervals referred to above; on the other hand, the 
CBZ monotherapy protocol resulted in a daily CBZ intake 
of around 800 mg/day, which is located in the middle/upper 
third of the typical dose range of CBZ applied to TN patients. 
These data show that the clinical result of  TN treatment with 
CBZ + ROP is superior to CBZ monotherapy, because the 
much lower dose of CBZ needed following the CBZ + ROP 
protocol will decrease the potential presence/intensity of 
adverse side effects. The possibility of CBZ subtherapeutic 
treatment in the CBZ + ROP or CBZ-only protocols was 
excluded, as shown by the significant pain intensity decrease 
associated with these therapeutical approaches.
Potential mechanisms underlying  
the effect of cBZ + ROP association
CBZ is involved in i) the recruitment of endogenous descend-
ing antinociceptive mechanisms by inhibiting noradrenaline 
uptake (a mechanism in part related to the action of some 
antidepressants) and ii) in the suppression of spontaneous 
neuronal activity, stabilization of hyperexcited neural mem-
branes, and/or reduction of propagation of synaptic impulses, 
due to CBZ modulation of voltage-gated sodium channels in 
a voltage- and frequency-dependent manner.12,36 Importantly, 
low-dose ROP has an analgesic action based, at least partly, 
on common mechanisms because both CBZ and ROP act 
on voltage-gated sodium channels37–40 by reducing ectopic 
neuronal activity without blocking nerve conduction. Major 
causes of ectopic firing include patches of demyelination, 
which can be present in TN at the trigeminal root entry zone 
or in focal areas resulting from microvascular nerve compres-
sion of the trigeminal nerve;12,41–43 the cellular mechanism 
that appears to underlie ectopic neuronal hyperexcitability is 
the remodeling of voltage-sensitive ion channels (including 
sodium channels), which are present at very low densities in 
the axonal membrane under myelin,44 but largely accumulate 
at sites of nerve injury and demyelination.45 Consequently, 
the ‘ignition hypothesis’ of TN46 postulates that pain parox-
ysms begin with discharge in a small cluster of trigeminal 
nerve afferents upon cutaneous trigger point stimulation, 
which when crossed after discharge ‘ignites’ activity and 
the recruitment of passive uninjured neighboring neurons; 
the augmented activity ignites additional passive neuronal 
fibers; and the resulting positive feedback chain reaction 
 triggers a  paroxysmal pain crisis.45 Thus, it is possible that 
the  therapeutic value of the present CBZ + ROP combination 
for CBZ in monotherapy may result from additive (and 
synergistic) i) control of peripheral fiber depolarization at trig-
ger points, ii) stabilization of uninjured passive neighboring 
neurons at the trigeminal ganglion (by both CBZ and ROP), 
and iii) increased action of noradrenaline at the synaptic cleft 
in the central nervous system (CBZ only).
Drug interactions of cBZ with 
concomitant drug therapies
Most patients with concomitant drug therapy were taking 
antihypertensors, namely angiotensin-converting enzyme 
inhibitors, which do not present known interactions with 
CBZ.47–49 CBZ may decrease serum concentrations of amio-
darone, levothyroxine, and warfarin,48,49 but to the best of our 
knowledge, the reversal has not been reported. The only two 
patients (in a total of 45) under drug therapy that may increase 
CBZ serum concentration were those taking fluoxetine, which 
may inhibit the hepatic metabolism of CBZ, or sodium val-
proate, which may prolong the elimination half-life of CBZ 
epoxide.48,49 However, it should be reinforced that neither these 
two patients nor the other 43 of this study presented evident 
side effects. This must have been achieved by i) the intense 
pain felt by patients arriving at the Pain Unit, which may have 
masked any putative CBZ side effects, and ii) the low/medium 
doses of CBZ that our team managed to achieve for sufficient 
pain control in CBZ + ROP and CBZ patients, respectively. 
Only one patient allocated to CBZ protocol was excluded from 
the study at day 1 due to an allergic reaction to CBZ.
Limitations of the study
Some important limitations can be included in the present 
study. Firstly, the generalization of findings to all patients 
who do not tolerate drug therapy after CBZ should be made 
with caution because no comparisons were made with adverse 
effects of other drugs that can be an alternative to the main 
classic treatment. The exclusion criteria were extensive and 
8.4% of TN patients arriving at the Pain Unit were with-
drawn from the study, which indicates that the study should 
be confirmed in larger-scale (less homogeneous) studies. 
 Secondly, although the effect of treatment on pain intensity 
and number of paroxysmal crises was still significantly 
different after 6 months of treatment with CBZ + ROP and 
CBZ, the follow-up period may not have been sufficient to 
determine the potentially long-term effects of the proposed 
treatment (unknown quiescent periods and pain-free intervals 
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that can reach months or years). Thirdly, no plasma levels of 
CBZ were measured in order to correlate the oral dose given 
with that really present in circulation.
Conclusions
CBZ is established as the first-line drug choice for pain control 
in TN. However, when CBZ fails to reduce pain or the adverse 
side effects do not allow increasing CBZ dosage, second-line 
drugs like gabapentin may solve the problem. Recently, an 
improvement of this second alternative has been achieved by 
the association of gabapentin with the peripheral analgesic 
block of TN trigger points with ROP. The same approach has 
been the objective of the present study, in order to improve the 
clinical outcome of CBZ therapy. We demonstrate that the asso-
ciation of CBZ and peripheral administration of ROP (CBZ 
+ ROP protocol) resulted in a clinically significant further 
improvement of the decrease in pain intensity already achieved 
by CBZ in monotherapy (CBZ protocol). This is accompanied 
with a clear decrease in the daily CBZ dosage needed for TN 
pain control, with a consequent potential reduction in the 
adverse side effects associated. Additionally, an NNT of 5 at 
the end of the treatment that reduces to 3 after a follow-up of 
5 months indicates that in long-lasting treatments with CBZ, 
the advantages of its association with the peripheral block with 
ROP increase with time. However, large-scale CBZ + ROP 
studies are needed to evaluate the dimension of the improve-
ment obtained by the association CBZ + ROP.
Acknowledgments
The authors thank the Clinical Director of the Hospital Center 
of Alto Ave (Fafe Unit), the Chronic Pain Unit team of the same 
Hospital, and Dr. Ramalho Fontes, the Director of the Depart-
ment of Neurology of Hospital S. Marcos, Braga (2006–2008), 
for the collaboration in this study. A special acknowledgment is 
given to Fundação para a Ciência e Tecnologia (FCT), FEDER, 
and Project Nr. PTDC/SAU-NEU/108557/2008 for supporting 
the publication of this study.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for 
the pharmacological management of neuropathic pain: an overview and 
literature update. Mayo Clin Proc. 2010;85 Suppl 3:S3–S14.
2. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefini-
tion and a grading system for clinical and research purposes. Neurology. 
2008;70:1630–1635.
3. Vadalouca A, Siafaka I, Argyra E, et al. Therapeutic management of 
chronic neuropathic pain: an examination of pharmacologic treatment. 
Ann N Y Acad Sci. 2006;1088:164–186.
 4. Katusic S, Williams DB, Beard CM, et al. Epidemiology and clinical 
features of idiopathic trigeminal neuralgia and glossopharyngeal neu-
ralgia: similarities and differences, Rochester, Minnesota, 1945–1984. 
Neuroepidemiology. 1991;10:276–281.
 5. Nurmikko TJ. Trigeminal neuralgia and other facial neuralgias. In: 
Cervero F, Jensen TS, editors. Handbook of Clinical Neurology: Pain. 
Vol 81 (3rd series). London: Elsevier; 2006:574–596.
 6. Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on 
trigeminal neuralgia management. Eur J Neurol. 2008;15:1013–1028.
 7. Hickey AH, Scrivani S, Bajwa Z. Cranial neuralgias. In: Fishman SM, 
Ballantyne JC, Rathmell JP, editors. Bonica’s Management of Pain. 
4th ed. London: Wolters Kluwer, Lippincott Williams & Wilkins; 
2010:953–972.
 8. Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic 
evaluation and treatment of trigeminal neuralgia (an evidence-based 
review): report of the Quality Standards Subcommittee of the American 
Academy of Neurology and the European Federation of Neurological 
Societies. Neurology. 2008;71:1183–1190.
 9. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm 
for neuropathic pain treatment: as evidence based proposal. Pain. 
2005;118:289–305.
 10. Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic man-
agement of neuropathic pain: evidence-based recommendations. Pain. 
2007;132:237–251.
 11. Jorns TP, Zakrzewska JM. Evidence-based approach to the medical man-
agement of trigeminal neuralgia. Br J Neurosurg. 2007;21:253–261.
 12. Cheshire WP. Trigeminal neuralgia: for one nerve a multitude of treat-
ments. Expert Rev Neurother. 2007;7:1565–1579.
 13. Narita H, Ozawa T, Nishiyama T, et al. An atypical case of fulminant 
interstitial pneumonitis induced by carbamazepine. Curr Drug Saf. 
2009;4:30–33.
 14. Gomez-Arguelles JM, Dorado R, Sepulveda JM, et al. Oxcarbazepine 
monotherapy in carbamazepine-unresponsive trigeminal neuralgia. 
J Clin Neurosci. 2008;15:516–519.
 15. Pérez C, Saldaña MT, Navarro A, et al. Trigeminal neuralgia treated 
with pregabalin in family medicine settings: its effect on pain alleviation 
and cost reduction. J Clin Pharmacol. 2009;49:582–590.
 16. Sist T, Filadora V, Miner M, et al. Gabapentin for idiopathic trigeminal 
neuralgia: report of two cases. Neurology. 1997;48:1467.
 17. Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis 
patients. Neurology. 1998;51:611–614.
 18. Solaro C, Messmer-Uccelli M, Uccelli A, et al. Low-dose gabapentin 
combined with either lamotrigine or carbamazepine can be useful 
therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol. 
2000;44:45–48.
 19. Cheshire WP. Defining the role for gabapentin in the treatment of 
trigeminal neuralgia: a retrospective study. J Pain. 2002;3:137–142.
 20. Pandey CK, Singh N, Singh PK. Gabapentin for refractory idiopathic 
trigeminal neuralgia. J Indian Med Assoc. 2008;106:124–125.
 21. Lemos L, Flores S, Oliveira P, et al. Gabapentin supplemented with 
ropivacain block of trigger points improves pain control and quality of 
life in trigeminal neuralgia patients when compared with gabapentin 
alone. Clin J Pain. 2008;24:64–75.
 22. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated 
guidelines for reporting parallel group randomised trials. PLoS Med. 
2010;7:3.
 23. Zakrzewska JM. Trigeminal, eye, and ear pain. In: Melzack R, 
Wall PD, editors. Handbook of Pain Management: A Clinical 
Companion to Wall and Melzack’s Textbook of Pain. London: Churchill 
Livingstone; 2003:199–215.
 24. Breivik H. Local anesthetic blocks and epidurals. In: McMahon SB, 
Koltzenburg M, editors. Melzack’s Textbook of Pain. 5th ed. London: 
Elsevier-Churchill Livingstone; 2006:903–925.
 25. Manchikanti L, Singh V, Trescot AM, et al. Guidelines for the practice 
of interventional techniques. In: Boswell MV, Cole BE, editors. Weiner’s 
Pain Management: A Practical Guide for Clinicians. 7th ed. London: 
CRS Press; 2006:847–878.
Journal of Pain Research
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/journal-of-pain-research-journal
The Journal of Pain Research is an international, peer-reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Journal of Pain Research 2010:3submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
212
Lemos et al
 26. Ahmad M, Goucke CR. Management strategies for the treatment of 
neuropathic pain in the elderly. Drugs Aging. 2002;19:929–945.
 27. Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically impor-
tant difference in pain outcome measures. Pain. 2000;88:287–294.
 28. Finnerup NB, Sindrup SH, Bach FW, et al. Lamotrigine in spinal 
cord injury pain: a randomized controlled trial. Pain. 2002;96: 
375–383.
 29. Salaffi F, Stancati A, Silvestri CA, et al. Minimal clinically important 
changes in chronic musculoskeletal pain intensity measured on a 
numerical rating scale. Eur J Pain. 2004;8:283–291.
 30. Hanley MA, Jensen MP, Ehde DM, et al. Clinically significant change 
in pain intensity ratings in persons with spinal cord injury or amputa-
tion. Clin J Pain. 2006;22:25–31.
 31. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clini-
cal importance of treatment outcomes in chronic pain clinical trials: 
IMMPACT recommendations. J Pain. 2008;9:105–121.
 32. McQuay HJ, Moore A. Methods of therapeutic trials. In: McMahon SB, 
Koltzenburg M, editors. Melzack’s Textbook of Pain. 5th ed. London: 
Elsevier-Churchill Livingstone; 2006:415–425.
 33. Altman DG. Confidence intervals for the number needed to treat. BMJ. 
1998;317:1309–1312.
 34. Zakrzewska JM, Lopez BC. Trigeminal and glossopharyngeal neuralgia. 
In: McMahon SB, Koltzenburg M, editors. Melzack’s Textbook of Pain. 
5th ed. London: Elsevier-Churchill Livingstone; 2006:1001–1010.
 35. Canavero S, Bonicalzi V. Drug therapy of trigeminal neuralgia. Expert 
Rev Neurother. 2006;6:429–440.
 36. Sang CN, Hayes KS. Anticonvulsivant medications in neuropathic pain. 
In: McMahon S, Koltzenburg M, editors. Wall and Melzack’s Textbook 
of Pain. 5th ed. London: Elsevier; 2006:964–976.
 37. Burchiel KJ. Carbamazepine inhibits spontaneous activity in experi-
mental neuromas. Exp Neurol. 1988;102:249–253.
 38. Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic 
neuroma and DRG discharge without blocking nerve conduction. Pain. 
1992;48:261–268.
 39. Liu BG, Zhuang XL, Li ST, Xu GH. The effects of ropivacaine on 
sodium currents in dorsal horn neurons of neonatal rats. Anesth Analg. 
2000;90:1034–1038.
 40. Rowbotham MC, Petersen KL. Anticonvulsants and local anesthetic 
drugs. In: Loeser JD, Butler SH, Chapman CR, Turk DC, editors. 
Bonica’s Management of Pain. 3rd ed. London: Lippincott Williams & 
Williams; 2001:329–341.
 41. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogen-
esis. Brain. 2001;124:2347–2360.
 42. Arrese I, Lagares A, Alday R, et al. Typical trigeminal neuralgia 
associated with brainstem white matter lesions on MRI in patients 
without criteria of multiple sclerosis. Acta Neurochir (Wien). 2008;150: 
1157–1161.
 43. Prasad S, Galetta S. Trigeminal neuralgia: historical notes and current 
concepts. Neurologist. 2009;15:87–94.
 44. Waxman SL, Kocsis J, Stys PK. The Axon. London: Oxford University 
Press; 1995.
 45. Devor M. Responses of nerves to injury in relation to neuropathic pain. 
In: McMahon SB, Koltzenburg M, editors. Melzack’s Textbook of Pain. 
5th ed. London: Elsevier-Churchill Livingstone; 2006:905–927.
 46. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self- sustaining 
discharge in the trigeminal ganglion. Pain. 1994;56:127–138.
 47. Patsalos PN, Perucca E. Clinically important drug interactions in 
 epilepsy: interactions between antiepileptic drugs and other drugs. 
Lancet Neurol. 2003;2:473–481.
 48. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. 
Br J Clin Pharmacol. 2006;61:246–255.
 49. Díaz RA, Sancho J, Serratosa J. Antiepileptic drug interactions. 
Neurologist. 2008;14(6 Suppl 1):S55–S65.
